Our results suggested that LPAATβ may play an important role in osteosarcoma and silencing LPAATβ may be exploited as a novel therapeutic strategy for the clinical management of cisplatin-resistance.
In conclusion, our study indicates that miR-24 is reduced in osteosarcoma cells, contributing to up-regulation of LPAATβ and resultant osteosarcoma cell proliferation.